Lena Allweiss Selected Research

Reinfection

1/2022	Therapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo.
1/2019	Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection.
1/2018	Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lena Allweiss Research Topics

Disease

27	Infections 03/2024 - 06/2011
6	Viremia 08/2017 - 06/2011
5	Coinfection 01/2023 - 03/2012
3	Persistent Infection 03/2024 - 04/2016
3	Reinfection 01/2022 - 01/2018
3	Chronic Hepatitis B 01/2020 - 06/2011
2	Fibrosis (Cirrhosis) 01/2023 - 01/2023
2	Hepatocellular Carcinoma (Hepatoma) 01/2019 - 01/2019
2	Hepatitis B 01/2019 - 08/2017
1	Chronic Hepatitis (Chronic Active Hepatitis) 01/2023
1	Hepatitis D 01/2023
1	Esophageal and Gastric Varices (Esophageal Varices) 01/2023
1	Chronic Hepatitis D 01/2023
1	Virus Diseases (Viral Diseases) 01/2023
1	Focal Nodular Hyperplasia 01/2019
1	Inflammation (Inflammations) 08/2015
1	Liver Diseases (Liver Disease) 08/2015
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 11/2014

Drug/Important Bio-Agent (IBA)

8	Antiviral Agents (Antivirals)IBA 06/2022 - 06/2011
7	Circular DNAIBA 03/2024 - 01/2017
6	myrcludex-BIBA 01/2022 - 03/2012
6	RNA (Ribonucleic Acid)IBA 01/2019 - 06/2011
3	Proteins (Proteins, Gene)FDA Link 01/2019 - 05/2013
3	Hepatitis delta Antigens (HDAg)IBA 01/2019 - 03/2012
3	InterferonsIBA 01/2018 - 06/2011
3	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 05/2013
3	AntigensIBA 01/2017 - 05/2013
2	Biomarkers (Surrogate Marker)IBA 03/2024 - 06/2023
2	bulevirtideIBA 01/2023 - 01/2023
2	sodium-bile acid cotransporterIBA 01/2021 - 01/2019
2	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2019 - 01/2017
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2019 - 08/2017
2	entecavir FDA Link 01/2018 - 01/2017
2	NucleosidesIBA 01/2018 - 01/2012
2	Interferon-alpha (Interferon Alfa)IBA 01/2017 - 03/2014
2	Hepatitis B Core AntigensIBA 01/2017 - 05/2013
2	LipopeptidesIBA 05/2013 - 03/2012
1	Tenofovir (Viread)FDA Link 01/2023
1	Toll-Like Receptor 2IBA 01/2020
1	NVR 3-778IBA 01/2018
1	Messenger RNA (mRNA)IBA 08/2017
1	Hepatitis B virus P proteinIBA 01/2017
1	AntibodiesIBA 05/2016
1	VaccinesIBA 04/2016
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 11/2014
1	Plasminogen Activators (Plasminogen Activator)IBA 11/2014
1	Peptides (Polypeptides)IBA 03/2012
1	NucleotidesIBA 01/2012

Therapy/Procedure

7	Therapeutics 04/2023 - 06/2011
1	Duration of Therapy 01/2023
1	Contraindications 01/2023
1	Injections 08/2017
1	Intravenous Injections 05/2016
1	Liver Transplantation 03/2014
1	Aftercare (After-Treatment) 05/2013